Eli Lilly (LLY): FY24 Q4 earnings call, Feb 6, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Feb 6, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Jaypirca”; 5 quoted, at least 25 words apart.
…We increased 3 percentage points in share of market in Q4 2024. Jaypirca worldwide revenue was $114 million, adding another solid quarter of sequential revenue…
…oncology, neuroscience and immunology to also grow revenue in 2025 as Ebglyss, Jaypirca, Omvoh and Kisunla launch upticks continue. At the portfolio level, we anticipate…
…failure and global submissions for imlunestrant for metastatic breast cancer and for Jaypirca with the BRUIN CLL-321 data. I'm also pleased to share that we've…
…body mass index of 27 or greater. We'll also see multiple additional Jaypirca data sets this year. Physician feedback is very positive on experience with…
…2 diabetes, tirzepatide for cardiovascular outcomes and multiple potential data sets for Jaypirca. 2025 will be another exciting year for Lilly R&D. Now I'll turn…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-02-06:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-02-06:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP